> News > Biopôle launches new collaboration with Bristol Myers Squibb

Biopôle launches new collaboration with Bristol Myers Squibb

Biopôle SA announces a new collaboration with Bristol Myers Squibb.  The collaboration will connect the leading global biopharma company with Biopôle’s innovation-rich life sciences community and ecosystem. This latest step in the expansion of Biopôle’s corporate network is expected to drive a host of new life sciences projects.

Biopôle offers a rich blend of industry and academia and this new collaboration will facilitate important connections and cooperation between Bristol Myers Squibb and the Biopôle community. As part of the Biopôle ecosystem, the company will enjoy immediate access to new technologies being developed on the campus. The array of emerging innovations at Biopôle have the potential to provide mutually beneficial opportunities for Biopôle’s corporate partners and community members. Biopôle will provide Bristol Myers Squibb with access to its scientific networks, biological chemistry and drug discovery activities in selected areas of interest. Corporate partners also enjoy the opportunity to participate in Biopôle’s innovation programmes StartLab and Digital Health Hub, get access to infrastructure, incubate new ideas and projects of interest, and host projects directly on campus.

James Carmichael, Vice President Integrative Sciences at Bristol Myers Squibb said, ‘We are pleased to collaborate with Biopôle and to continue to support the exciting science being conducted at this important research community.’

Nasri Nahas, CEO at Biopôle SA said, ‘We are excited to welcome Bristol Myers Squibb to our Corporate Partnership programme launched in 2020. We are confident that the research being conducted here at Biopôle has the potential to contribute to the company’s vision of transforming patients’ lives through science.’

Bristol Myers Squibb is a global biopharmaceutical company with a mission to discover, develop and deliver innovative medicines that help patients overcome serious diseases. The company has offices in Boudry, Switzerland.